New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Tasigna® (nilotinib) Capsules

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

Facts of Tasigna (Nilotinib)

Product: Tasigna® (nilotinib) Capsules
indication: blood cancer (chronic myelogenous leukemia-CML)
Strength: 200 mg hard capsules
Company: Novartis Pharmaceuticals Corporation

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Tasigna (Nilotinib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Tasigna (Nilotinib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

What Tasigna is?

Tasigna is a kinase inhibitor indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.

What Nilotinib is?

Nilotinib, sold under the brand name Tasigna, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. Nilotinib was approved for medical use in the United States in 2007. It is on the World Health Organization’s List of Essential Medicines.

Related Products